J INTERN MED:疑似稳定性冠心病患者循环三甲基赖氨酸水平与急性心肌梗死风险

2020-04-11 MedSci原创 MedSci原创

在疑似稳定型心绞痛患者中,血浆TML而非TMAO可以独立预测AMI的风险。该研究的结果促使人们对决定TML水平的代谢过程及其与心血管疾病之间潜在关联开展进一步研究。

肉碱前体三甲基赖氨酸(TML)与动脉粥样硬化的进展有关,可能与三甲胺-N-氧化物(TMAO)有关。核黄素是TMAO合成中的辅助因子。近日,内科学领域权威杂志Journal of Internal Medicine上发表一篇研究文章,研究人员旨在评估循环TML和TMAO与急性心肌梗塞(AMI)之间的关系,以及核黄素状态的潜在效应。

研究人员通过Cox建模,评估了4098例疑似稳定型心绞痛患者的风险关联,并根据血浆核黄素中位数进行了亚组分析。

在4.9年的中位随访期间,有336名(8.2%)患者发生AMI。TML第4和第1个四分位数的受试者进行比较,调整了年龄和性别的风险比(HR和95%CI为2.19(1.56-3.09))。传统心血管危险因素和肾功能指标的多变量调整只会使风险估计值稍有减弱(HR和95%CI为1.79(1.23-2.59)),在核黄素水平高于中位数的患者中尤为突出(P=0.035) 。血浆TML和TMAO密切相关(rs=0.41; p<0.001);然而,在调整后的分析中,血浆TMAO与AMI风险无关(HR和95%CI为0.81(0.58-1.14))。研究人员没有观察到TML和TMAO之间的相互作用。

由此可见,在疑似稳定型心绞痛患者中,血浆TML而非TMAO可以独立预测AMI的风险。该研究的结果促使人们对决定TML水平的代谢过程及其与心血管疾病之间潜在关联开展进一步研究。

原始出处:

Espen Ø. Bjørnestad,et al.Circulating trimethyllysine and risk of acute myocardial infarction in patients with suspected stable coronary heart disease.J INTERN MED. 2020.https://onlinelibrary.wiley.com/doi/10.1111/joim.13067

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1768925, encodeId=618a1e6892519, content=<a href='/topic/show?id=4d0d19e104e' target=_blank style='color:#2F92EE;'>#三甲基赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19710, encryptionId=4d0d19e104e, topicName=三甲基赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=047437947204, createdName=ms1260584454294838, createdTime=Mon Apr 20 04:49:45 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967756, encodeId=6ceb196e756b0, content=<a href='/topic/show?id=0c80e0373e2' target=_blank style='color:#2F92EE;'>#疑似稳定性冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70373, encryptionId=0c80e0373e2, topicName=疑似稳定性冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Sun Jan 24 12:49:45 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900523, encodeId=6d351900523ad, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Sun Oct 18 23:49:45 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381668, encodeId=625d38166882, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Apr 13 22:20:39 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447773, encodeId=1297144e77335, content=<a href='/topic/show?id=523a3082670' target=_blank style='color:#2F92EE;'>#冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30826, encryptionId=523a3082670, topicName=冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99445365987, createdName=liubm557, createdTime=Mon Apr 13 03:49:45 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552529, encodeId=85a615525299d, content=<a href='/topic/show?id=a8d5196997c' target=_blank style='color:#2F92EE;'>#三甲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19699, encryptionId=a8d5196997c, topicName=三甲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88e914287502, createdName=陈吴1239, createdTime=Mon Apr 13 03:49:45 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592171, encodeId=ed6415921e158, content=<a href='/topic/show?id=cce892599c3' target=_blank style='color:#2F92EE;'>#赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92599, encryptionId=cce892599c3, topicName=赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5e18091046, createdName=w363522455, createdTime=Mon Apr 13 03:49:45 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610424, encodeId=b770161042441, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Apr 13 03:49:45 CST 2020, time=2020-04-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1768925, encodeId=618a1e6892519, content=<a href='/topic/show?id=4d0d19e104e' target=_blank style='color:#2F92EE;'>#三甲基赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19710, encryptionId=4d0d19e104e, topicName=三甲基赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=047437947204, createdName=ms1260584454294838, createdTime=Mon Apr 20 04:49:45 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967756, encodeId=6ceb196e756b0, content=<a href='/topic/show?id=0c80e0373e2' target=_blank style='color:#2F92EE;'>#疑似稳定性冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70373, encryptionId=0c80e0373e2, topicName=疑似稳定性冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Sun Jan 24 12:49:45 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900523, encodeId=6d351900523ad, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Sun Oct 18 23:49:45 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381668, encodeId=625d38166882, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Apr 13 22:20:39 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447773, encodeId=1297144e77335, content=<a href='/topic/show?id=523a3082670' target=_blank style='color:#2F92EE;'>#冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30826, encryptionId=523a3082670, topicName=冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99445365987, createdName=liubm557, createdTime=Mon Apr 13 03:49:45 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552529, encodeId=85a615525299d, content=<a href='/topic/show?id=a8d5196997c' target=_blank style='color:#2F92EE;'>#三甲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19699, encryptionId=a8d5196997c, topicName=三甲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88e914287502, createdName=陈吴1239, createdTime=Mon Apr 13 03:49:45 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592171, encodeId=ed6415921e158, content=<a href='/topic/show?id=cce892599c3' target=_blank style='color:#2F92EE;'>#赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92599, encryptionId=cce892599c3, topicName=赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5e18091046, createdName=w363522455, createdTime=Mon Apr 13 03:49:45 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610424, encodeId=b770161042441, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Apr 13 03:49:45 CST 2020, time=2020-04-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1768925, encodeId=618a1e6892519, content=<a href='/topic/show?id=4d0d19e104e' target=_blank style='color:#2F92EE;'>#三甲基赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19710, encryptionId=4d0d19e104e, topicName=三甲基赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=047437947204, createdName=ms1260584454294838, createdTime=Mon Apr 20 04:49:45 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967756, encodeId=6ceb196e756b0, content=<a href='/topic/show?id=0c80e0373e2' target=_blank style='color:#2F92EE;'>#疑似稳定性冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70373, encryptionId=0c80e0373e2, topicName=疑似稳定性冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Sun Jan 24 12:49:45 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900523, encodeId=6d351900523ad, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Sun Oct 18 23:49:45 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381668, encodeId=625d38166882, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Apr 13 22:20:39 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447773, encodeId=1297144e77335, content=<a href='/topic/show?id=523a3082670' target=_blank style='color:#2F92EE;'>#冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30826, encryptionId=523a3082670, topicName=冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99445365987, createdName=liubm557, createdTime=Mon Apr 13 03:49:45 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552529, encodeId=85a615525299d, content=<a href='/topic/show?id=a8d5196997c' target=_blank style='color:#2F92EE;'>#三甲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19699, encryptionId=a8d5196997c, topicName=三甲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88e914287502, createdName=陈吴1239, createdTime=Mon Apr 13 03:49:45 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592171, encodeId=ed6415921e158, content=<a href='/topic/show?id=cce892599c3' target=_blank style='color:#2F92EE;'>#赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92599, encryptionId=cce892599c3, topicName=赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5e18091046, createdName=w363522455, createdTime=Mon Apr 13 03:49:45 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610424, encodeId=b770161042441, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Apr 13 03:49:45 CST 2020, time=2020-04-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1768925, encodeId=618a1e6892519, content=<a href='/topic/show?id=4d0d19e104e' target=_blank style='color:#2F92EE;'>#三甲基赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19710, encryptionId=4d0d19e104e, topicName=三甲基赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=047437947204, createdName=ms1260584454294838, createdTime=Mon Apr 20 04:49:45 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967756, encodeId=6ceb196e756b0, content=<a href='/topic/show?id=0c80e0373e2' target=_blank style='color:#2F92EE;'>#疑似稳定性冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70373, encryptionId=0c80e0373e2, topicName=疑似稳定性冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Sun Jan 24 12:49:45 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900523, encodeId=6d351900523ad, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Sun Oct 18 23:49:45 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381668, encodeId=625d38166882, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Apr 13 22:20:39 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447773, encodeId=1297144e77335, content=<a href='/topic/show?id=523a3082670' target=_blank style='color:#2F92EE;'>#冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30826, encryptionId=523a3082670, topicName=冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99445365987, createdName=liubm557, createdTime=Mon Apr 13 03:49:45 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552529, encodeId=85a615525299d, content=<a href='/topic/show?id=a8d5196997c' target=_blank style='color:#2F92EE;'>#三甲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19699, encryptionId=a8d5196997c, topicName=三甲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88e914287502, createdName=陈吴1239, createdTime=Mon Apr 13 03:49:45 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592171, encodeId=ed6415921e158, content=<a href='/topic/show?id=cce892599c3' target=_blank style='color:#2F92EE;'>#赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92599, encryptionId=cce892599c3, topicName=赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5e18091046, createdName=w363522455, createdTime=Mon Apr 13 03:49:45 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610424, encodeId=b770161042441, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Apr 13 03:49:45 CST 2020, time=2020-04-13, status=1, ipAttribution=)]
    2020-04-13 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1768925, encodeId=618a1e6892519, content=<a href='/topic/show?id=4d0d19e104e' target=_blank style='color:#2F92EE;'>#三甲基赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19710, encryptionId=4d0d19e104e, topicName=三甲基赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=047437947204, createdName=ms1260584454294838, createdTime=Mon Apr 20 04:49:45 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967756, encodeId=6ceb196e756b0, content=<a href='/topic/show?id=0c80e0373e2' target=_blank style='color:#2F92EE;'>#疑似稳定性冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70373, encryptionId=0c80e0373e2, topicName=疑似稳定性冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Sun Jan 24 12:49:45 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900523, encodeId=6d351900523ad, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Sun Oct 18 23:49:45 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381668, encodeId=625d38166882, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Apr 13 22:20:39 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447773, encodeId=1297144e77335, content=<a href='/topic/show?id=523a3082670' target=_blank style='color:#2F92EE;'>#冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30826, encryptionId=523a3082670, topicName=冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99445365987, createdName=liubm557, createdTime=Mon Apr 13 03:49:45 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552529, encodeId=85a615525299d, content=<a href='/topic/show?id=a8d5196997c' target=_blank style='color:#2F92EE;'>#三甲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19699, encryptionId=a8d5196997c, topicName=三甲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88e914287502, createdName=陈吴1239, createdTime=Mon Apr 13 03:49:45 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592171, encodeId=ed6415921e158, content=<a href='/topic/show?id=cce892599c3' target=_blank style='color:#2F92EE;'>#赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92599, encryptionId=cce892599c3, topicName=赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5e18091046, createdName=w363522455, createdTime=Mon Apr 13 03:49:45 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610424, encodeId=b770161042441, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Apr 13 03:49:45 CST 2020, time=2020-04-13, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1768925, encodeId=618a1e6892519, content=<a href='/topic/show?id=4d0d19e104e' target=_blank style='color:#2F92EE;'>#三甲基赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19710, encryptionId=4d0d19e104e, topicName=三甲基赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=047437947204, createdName=ms1260584454294838, createdTime=Mon Apr 20 04:49:45 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967756, encodeId=6ceb196e756b0, content=<a href='/topic/show?id=0c80e0373e2' target=_blank style='color:#2F92EE;'>#疑似稳定性冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70373, encryptionId=0c80e0373e2, topicName=疑似稳定性冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Sun Jan 24 12:49:45 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900523, encodeId=6d351900523ad, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Sun Oct 18 23:49:45 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381668, encodeId=625d38166882, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Apr 13 22:20:39 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447773, encodeId=1297144e77335, content=<a href='/topic/show?id=523a3082670' target=_blank style='color:#2F92EE;'>#冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30826, encryptionId=523a3082670, topicName=冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99445365987, createdName=liubm557, createdTime=Mon Apr 13 03:49:45 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552529, encodeId=85a615525299d, content=<a href='/topic/show?id=a8d5196997c' target=_blank style='color:#2F92EE;'>#三甲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19699, encryptionId=a8d5196997c, topicName=三甲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88e914287502, createdName=陈吴1239, createdTime=Mon Apr 13 03:49:45 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592171, encodeId=ed6415921e158, content=<a href='/topic/show?id=cce892599c3' target=_blank style='color:#2F92EE;'>#赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92599, encryptionId=cce892599c3, topicName=赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5e18091046, createdName=w363522455, createdTime=Mon Apr 13 03:49:45 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610424, encodeId=b770161042441, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Apr 13 03:49:45 CST 2020, time=2020-04-13, status=1, ipAttribution=)]
    2020-04-13 陈吴1239
  7. [GetPortalCommentsPageByObjectIdResponse(id=1768925, encodeId=618a1e6892519, content=<a href='/topic/show?id=4d0d19e104e' target=_blank style='color:#2F92EE;'>#三甲基赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19710, encryptionId=4d0d19e104e, topicName=三甲基赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=047437947204, createdName=ms1260584454294838, createdTime=Mon Apr 20 04:49:45 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967756, encodeId=6ceb196e756b0, content=<a href='/topic/show?id=0c80e0373e2' target=_blank style='color:#2F92EE;'>#疑似稳定性冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70373, encryptionId=0c80e0373e2, topicName=疑似稳定性冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Sun Jan 24 12:49:45 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900523, encodeId=6d351900523ad, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Sun Oct 18 23:49:45 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381668, encodeId=625d38166882, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Apr 13 22:20:39 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447773, encodeId=1297144e77335, content=<a href='/topic/show?id=523a3082670' target=_blank style='color:#2F92EE;'>#冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30826, encryptionId=523a3082670, topicName=冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99445365987, createdName=liubm557, createdTime=Mon Apr 13 03:49:45 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552529, encodeId=85a615525299d, content=<a href='/topic/show?id=a8d5196997c' target=_blank style='color:#2F92EE;'>#三甲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19699, encryptionId=a8d5196997c, topicName=三甲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88e914287502, createdName=陈吴1239, createdTime=Mon Apr 13 03:49:45 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592171, encodeId=ed6415921e158, content=<a href='/topic/show?id=cce892599c3' target=_blank style='color:#2F92EE;'>#赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92599, encryptionId=cce892599c3, topicName=赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5e18091046, createdName=w363522455, createdTime=Mon Apr 13 03:49:45 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610424, encodeId=b770161042441, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Apr 13 03:49:45 CST 2020, time=2020-04-13, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1768925, encodeId=618a1e6892519, content=<a href='/topic/show?id=4d0d19e104e' target=_blank style='color:#2F92EE;'>#三甲基赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19710, encryptionId=4d0d19e104e, topicName=三甲基赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=047437947204, createdName=ms1260584454294838, createdTime=Mon Apr 20 04:49:45 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967756, encodeId=6ceb196e756b0, content=<a href='/topic/show?id=0c80e0373e2' target=_blank style='color:#2F92EE;'>#疑似稳定性冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70373, encryptionId=0c80e0373e2, topicName=疑似稳定性冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Sun Jan 24 12:49:45 CST 2021, time=2021-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900523, encodeId=6d351900523ad, content=<a href='/topic/show?id=0983e529745' target=_blank style='color:#2F92EE;'>#稳定性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75297, encryptionId=0983e529745, topicName=稳定性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Sun Oct 18 23:49:45 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381668, encodeId=625d38166882, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Apr 13 22:20:39 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447773, encodeId=1297144e77335, content=<a href='/topic/show?id=523a3082670' target=_blank style='color:#2F92EE;'>#冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30826, encryptionId=523a3082670, topicName=冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99445365987, createdName=liubm557, createdTime=Mon Apr 13 03:49:45 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552529, encodeId=85a615525299d, content=<a href='/topic/show?id=a8d5196997c' target=_blank style='color:#2F92EE;'>#三甲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19699, encryptionId=a8d5196997c, topicName=三甲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88e914287502, createdName=陈吴1239, createdTime=Mon Apr 13 03:49:45 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592171, encodeId=ed6415921e158, content=<a href='/topic/show?id=cce892599c3' target=_blank style='color:#2F92EE;'>#赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92599, encryptionId=cce892599c3, topicName=赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5e18091046, createdName=w363522455, createdTime=Mon Apr 13 03:49:45 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610424, encodeId=b770161042441, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Apr 13 03:49:45 CST 2020, time=2020-04-13, status=1, ipAttribution=)]
    2020-04-13 智慧医人

相关资讯

Metabolism:L-高半胱氨酸亚磺酸、半胱氨酸和肉碱可作为急性心肌梗死高风险新的生物标志

总之,在有AMI风险受试者中检测到L-HCSA、CA以及肉碱的上调可以作为早期AMI检测的有前景的非侵入性生物标记。

Heart:合并症对急性心肌梗死患者肌钙蛋白峰值水平和死亡率的影响

在对AMI患者进行的这项全国性分析中,合并症严重影响了cTn峰值的全身浓度。无论cTn峰值水平如何,合并症都是死亡率的重要预测指标,在将cTn解释为诊断和预后生物标志物时,应将其考虑在内。

Circulation:2000年-2014年,急性心肌梗死发病率变化趋势的性别差异

近几十年来,美国急性心肌梗死(AMI)的发病率有所下降,但性别差异依然存在。在一个综合医疗服务系统中,Mefford等人研究了AMI事件在女性和男性中的时间趋势。研究人员在加利福尼亚州南部凯萨医疗机构中35岁及以上住院患者中筛选AMI患者。根据第九版临床修订的《国际疾病分类》鉴别2000年-2014年期间首次住院治疗的急性心肌梗死、ST段抬高型心肌梗死和非ST段抬高型心肌梗死患者。计算平均年变化百

Eur J Heart Fail:心源性休克并发急性心肌梗死的趋势

由此可见,并发AMI的心源性休克发生的频率已经有所降低,但是,CS(尤其是继发性CS)的死亡率也很高,尽管采用有创治疗的频率更高,但在过去的10年中并没有实质性的改善。

新型冠状病毒肺炎防控形势下急性心肌梗死诊治流程和路径中国专家共识(第1版)

自2019年12月以来,新型冠状病毒肺炎在武汉感染流行并迅速蔓延全国各地,根据国家整体防控方案,绝大部分地区启动限制出入、限制交通等措施。此特殊形势对于急性心肌梗死患者的转运救治流程提出了新的要求。急性心肌梗死发病急、致死性高、最佳救治窗口期短、且容易合并呼吸系统感染及呼吸、循环衰竭,更加需要就地积极治疗。为规范管理、易化流程,现制定急性心肌梗死诊治流程和路径策略,其核心是就近原则、安全防护原则、

BMJ:心力衰竭、急性心肌梗死或肺炎患者出院后急诊风险研究

研究发现,心力衰竭患者的出院预后相对于心肌梗死和肺炎较差,出院后30天急诊使用率高于心肌梗死和肺炎患者。